Swiss Machinery Stock News

ABB recently secured a contract to supply gearless mill drive and ring-geared mill drive systems for the Eva Copper Mine Project in Queensland, Australia, aiming to boost grinding efficiency, reliability and operational flexibility for the copper concentrator. This mining technology win highlights ABB’s role in enabling the energy transition through critical-minerals projects that increasingly demand efficient, low-risk processing solutions. We’ll now examine how winning a major copper mine...

UBS Group (SWX:UBSG) is in focus after Chairman Colm Kelleher warned that proposed Swiss capital rules could leave the bank as an international outlier and force difficult choices about future business priorities. See our latest analysis for UBS Group. The share price has moved up to CHF34.45, with a 1 month share price return of 15.14% and a 7 day gain of 5.29%. However, the 90 day share price return is a 9.39% decline and the year to date share price return is a 9.75% decline. At the same...

If you are wondering whether Alcon's current share price still reflects good value or if the market has already priced in the story, this article walks through the key numbers so you can judge that for yourself. Alcon shares last closed at US$63.90, with returns of 3.7% over the past week, 6.7% over the last 30 days and 0.6% year to date, while the 1 year return stands at a 14.9% decline. Recent headlines around Alcon have focused on its position in eye care and medical equipment, along with...

AI driven beauty launch puts Givaudan (SWX:GIVN) in focus Givaudan Active Beauty’s partnership with Haut.AI to showcase AI powered ingredient simulations at in cosmetics Global 2026 is drawing fresh attention to how the business connects scientific claims with consumer facing experiences. See our latest analysis for Givaudan. At a share price of CHF2,964.0, Givaudan has seen short term momentum pick up, with a 1 month share price return of 6.66% and 7 day gain of 5.56%. However, the 1 year...

It looks like UBS Group AG ( VTX:UBSG ) is about to go ex-dividend in the next three days. The ex-dividend date is...

Why Temenos Is On Investors’ Radar Today Temenos (SWX:TEMN) is drawing attention after a recent share price move, with the stock up 3% over the past day and about 10.5% over the past week, prompting a closer look at fundamentals. See our latest analysis for Temenos. That short burst of share price momentum, with a 10.53% 7 day share price return and the stock now at CHF77.7, sits against a year to date share price return of a 4.66% decline and a 1 year total shareholder return of 25.64%. This...

As European markets rally, buoyed by a U.S.-Iran ceasefire and positive investor sentiment, the pan-European STOXX Europe 600 Index has seen a notable increase of 3.05%. In this environment of cautious optimism, dividend stocks can offer an attractive proposition for investors seeking steady income streams amidst market fluctuations.

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see...

Nestlé S.A. ( VTX:NESN ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is commonly two business...

Cosmo Pharmaceuticals N.V. reported that shareholders at its recent Ordinary AGM approved all proposals, including a €2.10 per share dividend, with the ex-dividend date set for 24 April 2026 and payment on 11 May 2026. This broad shareholder backing for both governance items and a cash distribution highlights confidence in the company’s capital allocation approach and cash-generating capacity. We’ll now examine how this newly approved €2.10 dividend and strong shareholder support feed into...

R&S Group Holding AG recently reported its full-year 2025 results, with sales rising to CHF 414.84 million and net income reaching CHF 58.1 million, both higher than the prior year. The improvement in basic earnings per share from continuing operations to CHF 1.56 highlights enhanced profitability on a per-share basis alongside the company’s broader growth. With this earnings-driven backdrop and stronger per-share profitability, we will explore how these results shape R&S Group Holding’s...

In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for detecting neuroinflammation in adults with relapsing-remitting multiple sclerosis, enabling minimally invasive monitoring via its widely installed cobas instruments. This approval could materially change multiple sclerosis care pathways by shifting more frequent disease monitoring from hospital-based MRI scans to accessible, standardized blood testing. Next, we’ll...

Romande Energie Holding SA's ( VTX:REHN ) solid earnings announcement recently didn't do much to the stock price. We...

Idorsia’s pediatric insomnia data puts daridorexant in the spotlight Idorsia (SWX:IDIA) is back on investors’ radar after reporting statistically significant, dose dependent improvements in sleep time for children with insomnia treated with daridorexant, confirming safety and efficacy in patients as young as ten. See our latest analysis for Idorsia. Despite the positive pediatric insomnia data and the recent leadership change in clinical development, Idorsia’s CHF3.524 share price reflects...

Earlier in April 2026, ams-OSRAM reported stronger-than-expected trading, underpinned by improving margins and increased orders for its optical sensor portfolio in automotive and AI applications. The news highlighted how renewed demand for AI-related optical sensors is starting to influence perceptions of ams-OSRAM’s operational progress despite ongoing balance sheet and profitability challenges. We’ll now examine how this renewed interest in AI-related optical sensors could shape...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

SaltX recently reported that it has completed the first industrial-scale test period of electrified precalcination of Holcim’s cement raw meal at its ECRC facility in Hofors, Sweden, achieving positive calcination results and operational stability while processing around 20 tonnes per test run. This progress, alongside parallel work on electrified sintering and a fully electrified pilot plant targeted for 2028, highlights Holcim’s push to electrify and decarbonize cement production at an...

Earnings highlight and why it matters now R&S Group Holding (SWX:RSGN) just released its full year 2025 results, with sales of CHF 414.84 million, revenue of CHF 417.53 million, and net income of CHF 58.1 million drawing fresh attention to the stock. See our latest analysis for R&S Group Holding. The latest results appear to have kept momentum strong, with the share price at CHF24.2 and a 7 day share price return of 22.84% building on a 90 day share price return of 55.33%. The 3 year total...

Julius Bär Gruppe (SWX:BAER) is in the spotlight after a series of leadership changes, including the planned departure of finance chief Evie Kostakis and new board responsibilities for incoming non executive director Colin Bell. See our latest analysis for Julius Bär Gruppe. The executive reshuffle comes as the stock shows mixed momentum, with a 4.9% 1 month share price return and a 1 year total shareholder return of 33.7% contrasting with weaker recent quarterly performance. If leadership...

Medacta Group (SWX:MOVE) has stepped into an unusual spotlight after being selected to engineer a load bearing hip implant for a resurrected Tyrannosaurus rex as part of an international dinosaur revival project. See our latest analysis for Medacta Group. While the dinosaur project has put Medacta in the headlines, the CHF153.4 share price sits below its recent peak, with short term share price returns weaker. However, a 1 year total shareholder return of 34.52% still points to solid long...

Galderma Group (SWX:GALD) is back in focus after new clinical data on Sculptra and Restylane in menopause and medication driven weight loss, fresh nemolizumab results in pediatric atopic dermatitis, and the ALASTIN Signature Practices rollout. See our latest analysis for Galderma Group. The latest clinical readouts and the ALASTIN Signature Practices launch come after a mixed year for the shares, with a 5.83% 1 month share price return, a 3.27% 3 month share price decline, and a 1 year total...

C4 Therapeutics recently announced a collaboration with Roche to develop degrader-antibody conjugates for oncology, while Roche also launched its cobas MPX-E blood screening assay in CE-mark accepting countries, consolidating HIV and hepatitis virus detection into a single high-throughput test. Together, these moves underline Roche’s push to pair next-generation cancer modalities with advanced diagnostics that can improve laboratory efficiency and transfusion safety worldwide. We’ll now...

SoftwareOne Holding AG has released its 2025 results, reporting sales of CHF 1,243.4 million and net income of CHF 0.9 million, while proposing a reduced CHF 0.15 per share dividend and setting 2026 guidance for mid-single digit constant-currency revenue growth and a 30%–50% adjusted profit pay-out ratio. Alongside these figures, the company announced a leadership change in human resources, with long-time insider Nina Janorschke stepping in as Chief Human Resources Officer, which may help...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...